Skip to main content
Top
Published in: Respiratory Research 1/2022

01-12-2022 | Tuberculosis | Research

Development and validation of a prediction model for tuberculous pleural effusion: a large cohort study and external validation

Authors: Yanqing Liu, Zhigang Liang, Songbo Yuan, Shanshan Wang, Fei Guo, Weidong Peng, Jing Yang, Aihua Wu

Published in: Respiratory Research | Issue 1/2022

Login to get access

Abstract

Background

Distinguishing tuberculous pleural effusion (TPE) from non-tuberculosis (TB) benign pleural effusion (BPE) remains to be a challenge in clinical practice. The aim of the present study was to develop and validate a novel nomogram for diagnosing TPE.

Methods

In this retrospective analysis, a total of 909 consecutive patients with TPE and non-TB BPE from Ningbo First Hospital were divided into the training set and the internal validation set at a ratio of 7:3, respectively. The clinical and laboratory features were collected and analyzed by logistic regression analysis. A diagnostic model incorporating selected variables was developed and was externally validated in a cohort of 110 patients from another hospital.

Results

Six variables including age, effusion lymphocyte, effusion adenosine deaminase (ADA), effusion lactatedehy drogenase (LDH), effusion LDH/effusion ADA, and serum white blood cell (WBC) were identified as valuable parameters used for developing a nomogram. The nomogram showed a good diagnostic performance in the training set. A novel scoring system was then established based on the nomogram to distinguish TPE from non-TB BPE. The scoring system showed good diagnostic performance in the training set [area under the curve (AUC) (95% confidence interval (CI)), 0.937 (0.917–0.957); sensitivity, 89.0%, and specificity, 89.5%], the internal validation set [AUC (95%CI), 0.934 (0.902–0.966); sensitivity, 88.7%, and specificity, 90.3%], and the external validation set [(AUC (95%CI), 0.941 (0.891–0.991); sensitivity, 93.6%, and specificity, 87.5%)], respectively.

Conclusions

The study developed and validated a novel scoring system based on a nomogram originated from six clinical parameters. The novel scoring system showed a good diagnostic performance in distinguishing TPE from non-TB BPE and can be conveniently used in clinical settings.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P, et al. Global Tuberculosis Report 2020—reflections on the global TB burden, treatment and prevention efforts. Int J Infect Dis. 2021;113(Suppl 1):S7-s12.CrossRef Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P, et al. Global Tuberculosis Report 2020—reflections on the global TB burden, treatment and prevention efforts. Int J Infect Dis. 2021;113(Suppl 1):S7-s12.CrossRef
2.
go back to reference Diacon AH, Van de Wal BW, Wyser C, Smedema JP, Bezuidenhout J, Bolliger CT, et al. Diagnostic tools in tuberculous pleurisy: a direct comparative study. Eur Respir J. 2003;22:589–91.CrossRef Diacon AH, Van de Wal BW, Wyser C, Smedema JP, Bezuidenhout J, Bolliger CT, et al. Diagnostic tools in tuberculous pleurisy: a direct comparative study. Eur Respir J. 2003;22:589–91.CrossRef
3.
go back to reference Light RW. Update on tuberculous pleural effusion. Respirology. 2010;15:451–8.CrossRef Light RW. Update on tuberculous pleural effusion. Respirology. 2010;15:451–8.CrossRef
4.
go back to reference Zhai K, Lu Y, Shi HZ. Tuberculous pleural effusion. J Thorac Dis. 2016;8:E486–94.CrossRef Zhai K, Lu Y, Shi HZ. Tuberculous pleural effusion. J Thorac Dis. 2016;8:E486–94.CrossRef
5.
go back to reference Vorster MJ, Allwood BW, Diacon AH. Koegelenberg CF Tuberculous pleural effusions: advances and controversies. J Thorac Dis. 2015;7:981–91.PubMedPubMedCentral Vorster MJ, Allwood BW, Diacon AH. Koegelenberg CF Tuberculous pleural effusions: advances and controversies. J Thorac Dis. 2015;7:981–91.PubMedPubMedCentral
6.
go back to reference Agarwal R, Aggarwal AN, Gupta D. Diagnostic accuracy and safety of semirigid thoracoscopy in exudative pleural effusions: a meta-analysis. Chest. 2013;144:1857–67.CrossRef Agarwal R, Aggarwal AN, Gupta D. Diagnostic accuracy and safety of semirigid thoracoscopy in exudative pleural effusions: a meta-analysis. Chest. 2013;144:1857–67.CrossRef
7.
go back to reference Wang XJ, Yang Y, Wang Z, Xu LL, Wu YB, Zhang J, et al. Efficacy and safety of diagnostic thoracoscopy in undiagnosed pleural effusions. Respiration. 2015;90:251–5.CrossRef Wang XJ, Yang Y, Wang Z, Xu LL, Wu YB, Zhang J, et al. Efficacy and safety of diagnostic thoracoscopy in undiagnosed pleural effusions. Respiration. 2015;90:251–5.CrossRef
8.
go back to reference Shaikh F, Lentz RJ, Feller-Kopman D, Maldonado F. Medical thoracoscopy in the diagnosis of pleural disease: a guide for the clinician. Expert Rev Respir Med. 2020;14:987–1000.CrossRef Shaikh F, Lentz RJ, Feller-Kopman D, Maldonado F. Medical thoracoscopy in the diagnosis of pleural disease: a guide for the clinician. Expert Rev Respir Med. 2020;14:987–1000.CrossRef
9.
go back to reference Liu Y, Ou Q, Zheng J, Shen L, Zhang B, Weng X, et al. A combination of the QuantiFERON-TB gold in-tube assay and the detection of adenosine deaminase improves the diagnosis of tuberculous pleural effusion. Emerg Microbes Infect. 2016;5: e83.PubMedPubMedCentral Liu Y, Ou Q, Zheng J, Shen L, Zhang B, Weng X, et al. A combination of the QuantiFERON-TB gold in-tube assay and the detection of adenosine deaminase improves the diagnosis of tuberculous pleural effusion. Emerg Microbes Infect. 2016;5: e83.PubMedPubMedCentral
10.
go back to reference Chung JH, Han CH, Kim CJ, Lee SM. Clinical utility of QuantiFERON-TB GOLD In-Tube and tuberculin skin test in patients with tuberculous pleural effusions. Diagn Microbiol Infect Dis. 2011;71:263–6.CrossRef Chung JH, Han CH, Kim CJ, Lee SM. Clinical utility of QuantiFERON-TB GOLD In-Tube and tuberculin skin test in patients with tuberculous pleural effusions. Diagn Microbiol Infect Dis. 2011;71:263–6.CrossRef
11.
go back to reference Gopi A, Madhavan SM, Sharma SK, Sahn SA. Diagnosis and treatment of tuberculous pleural effusion in 2006. Chest. 2007;131:880–9.CrossRef Gopi A, Madhavan SM, Sharma SK, Sahn SA. Diagnosis and treatment of tuberculous pleural effusion in 2006. Chest. 2007;131:880–9.CrossRef
12.
go back to reference Lin MT, Wang JY, Yu CJ, Lee LN, Yang PC. Mycobacterium tuberculosis and polymorphonuclear pleural effusion: incidence and clinical pointers. Respir Med. 2009;103:820–6.CrossRef Lin MT, Wang JY, Yu CJ, Lee LN, Yang PC. Mycobacterium tuberculosis and polymorphonuclear pleural effusion: incidence and clinical pointers. Respir Med. 2009;103:820–6.CrossRef
13.
go back to reference Bielsa S, Palma R, Pardina M, Esquerda A, Light RW, Porcel JM. Comparison of polymorphonuclear- and lymphocyte-rich tuberculous pleural effusions. Int J Tuberc Lung Dis. 2013;17:85–9.CrossRef Bielsa S, Palma R, Pardina M, Esquerda A, Light RW, Porcel JM. Comparison of polymorphonuclear- and lymphocyte-rich tuberculous pleural effusions. Int J Tuberc Lung Dis. 2013;17:85–9.CrossRef
14.
go back to reference Villena Garrido V, Cases Viedma E, Fernández Villar A, de Pablo GA, Pérez Rodríguez E, Porcel Pérez JM, et al. Recommendations of diagnosis and treatment of pleural effusion. Update. Arch Bronconeumol. 2014;50:235–49.CrossRef Villena Garrido V, Cases Viedma E, Fernández Villar A, de Pablo GA, Pérez Rodríguez E, Porcel Pérez JM, et al. Recommendations of diagnosis and treatment of pleural effusion. Update. Arch Bronconeumol. 2014;50:235–49.CrossRef
15.
go back to reference Keng LT, Shu CC, Chen JY, Liang SK, Lin CK, Chang LY, et al. Evaluating pleural ADA, ADA2, IFN-γ and IGRA for diagnosing tuberculous pleurisy. J Infect. 2013;67:294–302.CrossRef Keng LT, Shu CC, Chen JY, Liang SK, Lin CK, Chang LY, et al. Evaluating pleural ADA, ADA2, IFN-γ and IGRA for diagnosing tuberculous pleurisy. J Infect. 2013;67:294–302.CrossRef
16.
go back to reference Jiang J, Shi HZ, Liang QL, Qin SM, Qin XJ. Diagnostic value of interferon-gamma in tuberculous pleurisy: a metaanalysis. Chest. 2007;131:1133–41.CrossRef Jiang J, Shi HZ, Liang QL, Qin SM, Qin XJ. Diagnostic value of interferon-gamma in tuberculous pleurisy: a metaanalysis. Chest. 2007;131:1133–41.CrossRef
17.
go back to reference Wang Z, Xu LL, Wu YB, Wang XJ, Yang Y, Zhang J, et al. Diagnostic value and safety of medical thoracoscopy in tuberculous pleural effusion. Respir Med. 2015;109:1188–92.CrossRef Wang Z, Xu LL, Wu YB, Wang XJ, Yang Y, Zhang J, et al. Diagnostic value and safety of medical thoracoscopy in tuberculous pleural effusion. Respir Med. 2015;109:1188–92.CrossRef
18.
go back to reference Rahman NM, Ali NJ, Brown G, Chapman SJ, Davies RJ, Downer NJ, et al. Local anaesthetic thoracoscopy: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65(Suppl 2):ii54-60.CrossRef Rahman NM, Ali NJ, Brown G, Chapman SJ, Davies RJ, Downer NJ, et al. Local anaesthetic thoracoscopy: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65(Suppl 2):ii54-60.CrossRef
19.
go back to reference WHO Guidelines Approved by the Guidelines Review Committee. In Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in Adults and Children: Policy Update. Geneva: World Health Organization. Copyright © World Health Organization 2013; 2013. WHO Guidelines Approved by the Guidelines Review Committee. In Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in Adults and Children: Policy Update. Geneva: World Health Organization. Copyright © World Health Organization 2013; 2013.
20.
go back to reference Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, et al. The New Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. mBio. 2017; 8. Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, et al. The New Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. mBio. 2017; 8.
21.
go back to reference Sehgal IS, Dhooria S, Aggarwal AN, Behera D, Agarwal R. Diagnostic performance of Xpert MTB/RIF in tuberculous pleural effusion: systematic review and meta-analysis. J Clin Microbiol. 2016;54:1133–6.CrossRef Sehgal IS, Dhooria S, Aggarwal AN, Behera D, Agarwal R. Diagnostic performance of Xpert MTB/RIF in tuberculous pleural effusion: systematic review and meta-analysis. J Clin Microbiol. 2016;54:1133–6.CrossRef
22.
go back to reference Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16:e173–80.CrossRef Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16:e173–80.CrossRef
23.
go back to reference Wang S, Tian S, Li Y, Zhan N, Guo Y, Liu Y, et al. Development and validation of a novel scoring system developed from a nomogram to identify malignant pleural effusion. EBioMedicine. 2020;58: 102924.CrossRef Wang S, Tian S, Li Y, Zhan N, Guo Y, Liu Y, et al. Development and validation of a novel scoring system developed from a nomogram to identify malignant pleural effusion. EBioMedicine. 2020;58: 102924.CrossRef
24.
go back to reference Wu A, Liang Z, Yuan S, Wang S, Peng W, Mo Y, et al. Development and validation of a scoring system for early diagnosis of malignant pleural effusion based on a nomogram. Front Oncol. 2021;11: 775079.CrossRef Wu A, Liang Z, Yuan S, Wang S, Peng W, Mo Y, et al. Development and validation of a scoring system for early diagnosis of malignant pleural effusion based on a nomogram. Front Oncol. 2021;11: 775079.CrossRef
25.
go back to reference Michot JM, Madec Y, Bulifon S, Thorette-Tcherniak C, Fortineau N, Noël N, et al. Adenosine deaminase is a useful biomarker to diagnose pleural tuberculosis in low to medium prevalence settings. Diagn Microbiol Infect Dis. 2016;84:215–20.CrossRef Michot JM, Madec Y, Bulifon S, Thorette-Tcherniak C, Fortineau N, Noël N, et al. Adenosine deaminase is a useful biomarker to diagnose pleural tuberculosis in low to medium prevalence settings. Diagn Microbiol Infect Dis. 2016;84:215–20.CrossRef
26.
go back to reference Garcia-Zamalloa A, Taboada-Gomez J. Diagnostic accuracy of adenosine deaminase and lymphocyte proportion in pleural fluid for tuberculous pleurisy in different prevalence scenarios. PLoS ONE. 2012;7: e38729.CrossRef Garcia-Zamalloa A, Taboada-Gomez J. Diagnostic accuracy of adenosine deaminase and lymphocyte proportion in pleural fluid for tuberculous pleurisy in different prevalence scenarios. PLoS ONE. 2012;7: e38729.CrossRef
27.
go back to reference Lei X, Wang J, Yang Z, Zhou S, Xu Z. Diagnostic value of pleural effusion mononuclear cells count and adenosine deaminase for tuberculous pleurisy patients in China: a case-control study. Front Med (Lausanne). 2019;6:301.CrossRef Lei X, Wang J, Yang Z, Zhou S, Xu Z. Diagnostic value of pleural effusion mononuclear cells count and adenosine deaminase for tuberculous pleurisy patients in China: a case-control study. Front Med (Lausanne). 2019;6:301.CrossRef
28.
go back to reference Manuel Porcel J, Vives M, Esquerda A, Ruiz A. Usefulness of the British Thoracic Society and the American College of Chest Physicians guidelines in predicting pleural drainage of non-purulent parapneumonic effusions. Respir Med. 2006;100:933–7.CrossRef Manuel Porcel J, Vives M, Esquerda A, Ruiz A. Usefulness of the British Thoracic Society and the American College of Chest Physicians guidelines in predicting pleural drainage of non-purulent parapneumonic effusions. Respir Med. 2006;100:933–7.CrossRef
29.
go back to reference Porcel JM, Esquerda A, Bielsa S. Diagnostic performance of adenosine deaminase activity in pleural fluid: a single-center experience with over 2100 consecutive patients. Eur J Intern Med. 2010;21:419–23.CrossRef Porcel JM, Esquerda A, Bielsa S. Diagnostic performance of adenosine deaminase activity in pleural fluid: a single-center experience with over 2100 consecutive patients. Eur J Intern Med. 2010;21:419–23.CrossRef
30.
go back to reference Davies CW, Gleeson FV, Davies RJ. BTS guidelines for the management of pleural infection. Thorax. 2003;58(Suppl 2):ii18-28.CrossRef Davies CW, Gleeson FV, Davies RJ. BTS guidelines for the management of pleural infection. Thorax. 2003;58(Suppl 2):ii18-28.CrossRef
31.
go back to reference Wang J, Liu J, Xie X, Shen P, He J, Zeng Y. The pleural fluid lactate dehydrogenase/adenosine deaminase ratio differentiates between tuberculous and parapneumonic pleural effusions. BMC Pulm Med. 2017;17:168.CrossRef Wang J, Liu J, Xie X, Shen P, He J, Zeng Y. The pleural fluid lactate dehydrogenase/adenosine deaminase ratio differentiates between tuberculous and parapneumonic pleural effusions. BMC Pulm Med. 2017;17:168.CrossRef
32.
go back to reference Blakiston M, Chiu W, Wong C, Morpeth S, Taylor S. Diagnostic performance of pleural fluid adenosine deaminase for tuberculous pleural effusion in a low-incidence setting. J Clin Microbiol. 2018; 56. Blakiston M, Chiu W, Wong C, Morpeth S, Taylor S. Diagnostic performance of pleural fluid adenosine deaminase for tuberculous pleural effusion in a low-incidence setting. J Clin Microbiol. 2018; 56.
Metadata
Title
Development and validation of a prediction model for tuberculous pleural effusion: a large cohort study and external validation
Authors
Yanqing Liu
Zhigang Liang
Songbo Yuan
Shanshan Wang
Fei Guo
Weidong Peng
Jing Yang
Aihua Wu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2022
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-022-02051-4

Other articles of this Issue 1/2022

Respiratory Research 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine